There is no hazardous surcharge associated with this product.
There is no packaging charge associated with this product.
For Research Purposes only. Not for Personal use.
All compounds supplied are strictly intended for laboratory, research, analytical, and scientific use only. They are not meant for human consumption, therapeutic use, or any form of clinical application.
Sodium 4-(3-(3-((4-acetyl-3-hydroxy-2-propylphenyl)thio)propoxy-d6)-6-(1-hydroxyethyl)-2-propylphenoxy)butanoate; MN-002-d6 Sodium Salt
Application Notes
"Hydroxy Tipelukast-d6 Sodium Salt has shown to improve symptoms of fatty liver, lobular inflammation hepatocyte hypertrophy and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH)."
Hazard Compound
Refer MSDS for complete information.
Overview
"Hydroxy Tipelukast-d6 Sodium Salt has shown to improve symptoms of fatty liver, lobular inflammation hepatocyte hypertrophy and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH)."
